MediPoint: Drug-Eluting Balloons - APAC Analysis and Market Forecasts

Summary

GlobalData has released its medical devices report, “MediPoint: Drug-Eluting Balloons - APAC Analysis and Market Forecasts”. The report is an essential source of information and analysis on the drug-eluting balloons (DEB) market in Asia-Pacific (APAC). The report provides in-depth insight into the use of DEB for coronary and peripheral applications in the lower extremity including in-stent restenosis, bifurcation lesions, small vessel disease, femoropopliteal artery and below-the-knee lesions, chronic total occlusions, acute myocardial infarction and lesions in diabetics.

The DEB market in three APAC countries including Japan, China and India was assessed to identify and determine whether the current unmet needs are addressed, understand the challenges of DEB angioplasty and evaluate the current and future adoption of DEB for select coronary and peripheral indications. The APAC sales expectations are discussed through careful analysis of adoption patterns of using these DEB.

Clients can use this report to better understand the scope of this technology and for strategic planning to explore opportunities in this dynamic market. The report also provides insights into the competitive landscape, the marketed and pipeline DEB products, the current and emerging players and comparative market analysis of different types of interventional techniques used to treat coronary and peripheral artery disease. This report is built using data and information sourced from secondary sources and primary research interviews and survey with leading Interventional Cardiologists and Interventional Radiologists, with in-house analysis conducted by GlobalData’s team of industry experts.

Scope

- An overview of coronary artery disease and peripheral artery disease in the lower extremity, which includes epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.

- Annualized total drug-eluting balloon market revenue by type of disease, annual cost of disease and drug-eluting balloons adoption pattern and procedure data in APAC from 2010-2012 and forecast for seven years to 2019.

- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in the three APAC countries covered in the report, and implications of the drug-eluting balloon market.

- Pipeline analysis: comprehensive data split across different stages of development, emerging trends and DEB designs in development, including investigation of DEB coating technology, antiproliferative agent used, balloon and catheter design and durability.

- Analysis of the current and future market competition in the APAC drug-eluting balloon market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the DEB market in APAC.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the APAC DEB market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track device sales in the APAC DEB market by disease and indication from 2010-2019.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

1 Table of Contents
1 Table of Contents 8


2 Introduction 26
2.1 Catalyst 27
3 Disease Overview 29
3.1 Overview 29
3.1.1 Coronary Artery Disease 29
3.1.2 Peripheral Artery Disease 29
3.2 Anatomy and Physiology 30
3.2.1 Coronary Arteries 30
3.2.2 Peripheral Arteries of the Lower Extremity 31
3.3 Pathophysiology 33
3.3.1 Coronary Artery Disease 33
3.3.2 Peripheral Artery Disease 34
3.4 Clinical Presentation 35
3.4.1 Symptoms 35
3.4.2 Risk Factors 38
3.4.3 Disease Classification 39
3.4.4 Diagnosis 41
3.4.5 Clinical Outcomes 44
3.5 Epidemiology 77
3.5.1 Coronary Artery Disease 77
3.5.2 Peripheral Artery Disease 80
3.6 Economic Impact of Coronary and Peripheral Artery Disease 83
3.6.1 Cost of Coronary Artery Disease 83
3.6.2 Cost of Peripheral Artery Disease 84
4 Competitive Assessment 85
4.1 Overview 85
4.2 Product Profiles by Company 87
4.2.1 Aachen Resonance 88
4.2.2 B. Braun 90
4.2.3 Biotronik 96
4.2.4 Blue Medical 99
4.2.5 Cardionovum 106
4.2.6 C.R. Bard 112
4.2.7 Concept Medical Research 118
4.2.8 Cook Medical 122
4.2.9 Eurocor 124
4.2.10 Medrad (Bayer Healthcare) 138
4.2.11 Medtronic 141
4.2.12 Minvasys 149
5 Unmet Needs 152
5.1 Need for Better Clinical Outcomes in Specific Lesions 152
5.1.1 Chronic Total Occlusions 152
5.1.2 Small-Vessel Coronary Lesions 153
5.1.3 Long Lesions 153
5.1.4 Heavily-Calcified and Uncrossable/Undilatable Lesions 154
5.1.5 Bifurcation Lesions 154
5.2 Need for Better Revascularization of the Femoropopliteal Artery 155
5.3 Difficulty in Treating the Infrapopliteal Artery 157
5.4 Eliminating Mechanisms of Failure with Balloon Angioplasty 158
5.5 Addressing Challenges of Stenting 160
5.5.1 Risk of Post-Procedural Complications 160
5.5.2 In-Stent Restenosis 161
5.5.3 Stent-In-Stent Procedures 163
5.5.4 Prolonged Dual Antiplatelet Therapy 164
5.5.5 Lack of Homogenous Drug Distribution 165
5.5.6 Delayed Healing 165
5.5.7 Stent Fracture 166
5.5.8 Negative Vessel Remodeling 167
5.5.9 Long-Term Vessel Patency 167
5.6 Need for Effective Therapy for Specific Patient Populations 168
5.7 Lack of Clinical Data 169
5.8 Addressing the Complications of Bypass Surgery 169
5.9 Need to Improve Medical Therapy 170
5.10 Comparative Studies on Exercise Therapy for PAD 171
6 Pipeline Products 172
6.1 Overview 172
6.2 Pipeline by Stage of Development 173
6.3 Pipeline Product Profiles 175
6.3.1 NF-?B Decoy Oligo DEB 175
6.3.2 Drug-Coated AngioSculpt 177
6.3.3 BioPath 180
6.3.4 BioStream 181
6.3.5 Boston Scientific Drug-Coated Balloon 182
6.3.6 Coroflex DEBlue 183
6.3.7 Covidien Drug-Coated Balloon 185
6.3.8 Caliber Therapeutics DEB 187
6.3.9 Elixir Medical Corporation DCB 188
6.3.10 LifeTech Scientific Corporation DEB 188
6.3.11 Micell Technologies Drug-Coated Balloon 188
6.3.12 Drug-Coated Chocolate DEB 190
6.3.13 Passeo-18 Lux 192
6.3.14 Vascular Nanotransfer Technologies Drug-Coated Balloon 193
6.3.15 WOMBAT DCB 194
7 Clinical Trial Analysis 196
7.1 Overview 196
7.2 Clinical Trials to Watch 196
7.2.1 Drug-Eluting Balloons 196
7.2.2 Vascular Stents 209
8 Industry Overview 215
8.1 Procedure Trends 215
8.1.1 Factors Contributing to the Rise of Coronary and Peripheral Interventions 215
8.1.2 Coronary Artery Disease 215
8.1.3 Peripheral Artery Disease 217
8.2 Physician Decision-Making Process 219
8.3 Market Access 221
8.3.1 Regulatory Process 222
8.3.2 Adoption 224
8.3.3 Reimbursement Trends in the Asia-Pacific Region 227
8.4 Regulatory Issues/Recalls 230
8.4.1 Regulatory Issues 230
8.4.2 Product Recalls 231
8.5 Mergers and Acquisitions/Partnerships 231
8.5.1 Biosensors International and Eurocor 231
8.5.2 Boston Scientific Corporation and Guidant Corporation 232
8.5.3 Covidien and ev3, CV Ingenuity 232
8.5.4 C.R. Bard and Lutonix 233
8.5.5 Micell Technologies and Maxcor Lifescience 233
8.5.6 Medrad and Bayer 234
8.5.7 Medtronic and Invatec 234
9 Current and Future Players 235
9.1 Overview 235
9.2 Trends in Corporate Strategy 236
9.3 Company Profiles 239
9.3.1 Aachen Resonance 239
9.3.2 AnGes MG 240
9.3.3 AngioScore 242
9.3.4 AVIDAL Vascular 244
9.3.5 B. Braun 246
9.3.6 Biosensors International 248
9.3.7 Biotronik 250
9.3.8 Blue Medical 252
9.3.9 Boston Scientific Corporation 254
9.3.10 Caliber Therapeutics 256
9.3.11 Cardionovum 258
9.3.12 Concept Medical Research 260
9.3.13 Cook Medical 262
9.3.14 Covidien 264
9.3.15 C.R. Bard 266
9.3.16 Elixir Medical Corporation 268
9.3.17 Eurocor 270
9.3.18 LifeTech Scientific Corporation 272
9.3.19 Medtronic 274
9.3.20 Micell Technologies 276
9.3.21 Minvasys 277
9.3.22 TriReme Medical 279
9.3.23 Vascular Nanotransfer Technologies 281
10 Market Drivers, Opportunities, Barriers and Substitutes 283
10.1 Market Drivers 283
10.1.1 Rising Prevalence of Disease 284
10.1.2 Viable Treatment for Select Indications 285
10.1.3 No Metal Left Behind 290
10.1.4 Avoid Stent-in-Stent Procedures 291
10.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 292
10.1.6 Enhanced Vessel Healing and Better Patency 292
10.1.7 Technical Feasibility of Future Interventions 293
10.1.8 DEB as an Adjunctive Therapy 294
10.1.9 Limb Amputation 294
10.1.10 Cost Savings 295
10.1.11 Availability of Long-Term and Cost-Effective Data 296
10.1.12 Launch of DEB in the US 296
10.2 Opportunities 297
10.2.1 Improve DEB Design 297
10.2.2 DEB Hybrid Systems (DEB + Stent) 301
10.2.3 Target Indications Where Stenting is Not Satisfactory 302
10.2.4 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 305
10.2.5 Target Challenging Patient Populations 306
10.2.6 Launch DEB in the Japanese Market 307
10.2.7 Emerging Markets 308
10.3 Market Barriers 308
10.3.1 Slow Adoption 308
10.3.2 High Selling Prices 312
10.3.3 Lack of Reimbursement 313
10.3.4 US FDA Regulatory Challenges 314
10.3.5 Healthcare Cost-Cutting and Reimbursement 315
10.3.6 Availability of Venture Capital 316
10.3.7 Medical Device Excise Tax 317
10.4 Market Substitutes 317
10.4.1 Vascular Stents 317
10.4.2 Liquid Drug Delivery Catheter 321
11 Drug-Eluting Balloon Market Analysis 324
11.1 APAC Market Overview 324
11.2 Market Analysis by Type of Disease 325
11.2.1 Coronary Artery Disease 325
11.2.2 Peripheral Artery Disease in the Lower Extremity 326
11.3 Market Distribution by Indication 328
11.4 Primary Versus Adjunctive Therapy 330
11.5 Comparative Market Analysis 332
11.5.1 Coronary Artery Disease 332
11.5.2 Peripheral Artery Disease in the Lower Extremity 334
12 Country Outlooks and Forecasts 336
12.1 Overview 336
12.2 Japan 337
12.2.1 Overview 337
12.2.2 Market Analysis 337
12.3 China 340
12.3.1 Overview 340
12.3.2 Market Analysis 340
12.4 India 343
12.4.1 Overview 343
12.4.2 Market Analysis 343
13 Appendix 346
13.1 Bibliography 346
13.2 Abbreviations 371
13.3 Report Methodology 375
13.3.1 Overview 375
13.3.2 Coverage 375
13.3.3 Secondary Research 375
13.3.4 Forecasting Methodology 376
13.4 Physicians and Specialists Included in this Study 378
13.5 Physician Survey 381
13.6 About the Authors 382
13.6.1 Analysts 382
13.6.2 Global Head of Healthcare 383
13.7 About MediPoint 384
13.8 About GlobalData 384
13.9 Disclaimer 384

1.1 List of Tables
Table 1: Classification Systems for Determining the Severity of PAD Symptoms 37
Table 2: Risk Factors Associated with CAD and PAD 38
Table 3: Types of Atherosclerotic Lesions 40
Table 4: Treatment Guidelines to Improve the Symptoms of CAD* 45
Table 5: TASC II Classification of Iliac Artery Lesions 47
Table 6: TASC II Classification of Femoropopliteal Artery Lesions 48
Table 7: TASC II Classification of Infrapopliteal Artery Lesions 49
Table 8: Types of Coronary Artery Bypass Grafting 60
Table 9: Complications of Coronary/Peripheral Artery Bypass Surgery 61
Table 10: Indications for Using Drug-Eluting Balloons 64
Table 11: Drug-Eluting Balloon Coating Characteristics 67
Table 12: Drugs Incorporated Into Drug-Eluting Stents 70
Table 13: Types of Lesions Treated Using Atherectomy 73
Table 14: Prevalence of CAD in the Population Age ?65 Years in the APAC Market (millions), 2010-2019 78
Table 15: Prevalence of PAD in the Population Age ?65 Years in the APAC Market (millions), 2010-2019 81
Table 16: Direct and Indirect Healthcare Costs 83
Table 17: APAC DEB Market ($m) for Treating Coronary and Peripheral Artery Disease, 2012 85
Table 18: Marketed DEB Products 87
Table 19: Elutax SV Product Portfolio 88
Table 20: Elutax SV SWOT Analysis, 2013 90
Table 21: SeQuent Please Product Portfolio 91
Table 22: SeQuent Please SWOT Analysis, 2013 96
Table 23: Pantera Lux Product Portfolio 97
Table 24: Pantera Lux SWOT Analysis, 2013 99
Table 25: Pioneer Product Portfolio 100
Table 26: Pioneer SWOT Analysis, 2013 102
Table 27: Protege Product Portfolio 103
Table 28: Protege SWOT Analysis, 2013 106
Table 29: Restore DEB Product Portfolio 107
Table 30: Restore DEB SWOT Analysis, 2013 108
Table 31: Legflow DEB Product Portfolio 109
Table 32: Legflow DEB SWOT Analysis, 2013 111
Table 33: Other DEB Products Developed by Cardionovum 112
Table 34: Lutonix Product Portfolio 113
Table 35: Lutonix SWOT Analysis, 2013 118
Table 36: Magic Touch Product Portfolio 119
Table 37: Magic Touch SWOT Analysis, 2013 121
Table 38: Advance 18 PTX Product Portfolio 122
Table 39: Advance 18 PTX SWOT Analysis, 2013 124
Table 40: Dior Product Portfolio 125
Table 41: Dior SWOT Analysis, 2013 131
Table 42: Freeway Family of DEB Product Portfolio 132
Table 43: Freeway Family of DEB SWOT Analysis, 2013 135
Table 44: Magical Product Portfolio 136
Table 45: Magical SWOT Analysis, 2013 138
Table 46: Cotavance Product Portfolio 139
Table 47: Cotavance SWOT Analysis, 2013 141
Table 48: IN.PACT Family DEB Product Portfolio 142
Table 49: IN.PACT SWOT Analysis, 2013 149
Table 50: Danubio Product Portfolio 150
Table 51: Danubio SWOT Analysis, 2013 151
Table 52: Global DEB Pipeline Products 174
Table 53: NF-?B Decoy Oligo DEB SWOT Analysis, 2013 177
Table 54: AngioSculpt SWOT Analysis, 2013 179
Table 55: BioPath SWOT Analysis, 2013 181
Table 56: BioStream SWOT Analysis, 2013 182
Table 57: Boston Scientific DEB SWOT Analysis, 2013 183
Table 58: Coroflex DEBlue SWOT Analysis, 2013 185
Table 59: Covidien DCB SWOT Analysis, 2013 187
Table 60: Micell Technologies’ DCB SWOT Analysis, 2013 189
Table 61: Drug-Coated Chocolate DEB SWOT Analysis, 2013 191
Table 62: Passeo-18 Lux SWOT Analysis, 2013 193
Table 63: Vascular Nanotransfer Technologies DCB SWOT Analysis, 2013 194
Table 64: WOMBAT DCB SWOT Analysis, 2013 195
Table 65: Reimbursement Classification of Medical Devices in Japan 228
Table 66: Aachen Resonance Company Profile 239
Table 67: Aachen Resonance, Marketed DEB Product 240
Table 68: Aachen Resonance SWOT Analysis, 2013 240
Table 69: AnGes MG Company Profile 241
Table 70: AnGes MG, Pipeline DEB Product 242
Table 71: AnGes MG SWOT Analysis, 2013 242
Table 72: AngioScore Company Profile 243
Table 73: AngioScore, Pipeline DEB Product 243
Table 74: AngioScore SWOT Analysis, 2013 244
Table 75: AVIDAL Vascular Company Profile 244
Table 76: AVIDAL Vascular, Pipeline DEB Product 245
Table 77: AVIDAL Vascular SWOT Analysis, 2013 246
Table 78: B. Braun Company Profile 246
Table 79: B. Braun, Marketed and Pipeline DEB Products 247
Table 80: B. Braun SWOT Analysis, 2013 248
Table 81: Biosensors International Company Profile 249
Table 82: Biosensors International, Pipeline DEB Products 249
Table 83: Biosensors International SWOT Analysis, 2013 250
Table 84: Biotronik Company Profile 251
Table 85: Biotronik, Marketed and Pipeline DEB Products 251
Table 86: Biotronik SWOT Analysis, 2013 252
Table 87: Blue Medical Company Profile 253
Table 88: Blue Medical, Marketed DEB Products 254
Table 89: Blue Medical SWOT Analysis, 2013 254
Table 90: Boston Scientific Corporation Company Profile 255
Table 91: Boston Scientific Corporation, Pipeline DEB Product 255
Table 92: Boston Scientific Corporation SWOT Analysis, 2013 256
Table 93: Caliber Therapeutics Company Profile 256
Table 94: Caliber Therapeutics, Pipeline DEB Product 257
Table 95: Caliber Therapeutics SWOT Analysis, 2013 258
Table 96: Cardionovum Company Profile 258
Table 97: Cardionovum, Marketed and Pipeline DEB Products 259
Table 98: Cardionovum SWOT Analysis, 2013 260
Table 99: Concept Medical Research Company Profile 260
Table 100: Concept Medical Research, Marketed DEB Product 261
Table 101: Concept Medical Research SWOT Analysis, 2013 262
Table 102: Cook Medical Company Profile 262
Table 103: Cook Medical, Marketed DEB Product 263
Table 104: Cook Medical SWOT Analysis, 2013 264
Table 105: Covidien Company Profile 265
Table 106: Covidien, Pipeline DEB Product 265
Table 107: Covidien SWOT Analysis, 2013 266
Table 108: C.R. Bard Company Profile 266
Table 109: C.R. Bard, Marketed DEB Products 267
Table 110: C.R. Bard SWOT Analysis, 2013 268
Table 111: Elixir Medical Corporation Company Profile 268
Table 112: Elixir Medical Corporation, Pipeline DEB Product 269
Table 113: Elixir Medical Corporation SWOT Analysis, 2013 269
Table 114: Eurocor Company Profile 270
Table 115: Eurocor, Marketed DEB Products 271
Table 116: Eurocor SWOT Analysis, 2013 271
Table 117: LifeTech Scientific Corporation Company Profile 272
Table 118: LifeTech Scientific, Pipeline DEB Product 273
Table 119: LifeTech Scientific SWOT Analysis, 2013 273
Table 120: Medtronic Company Profile 274
Table 121: Medtronic, Marketed DEB Products 275
Table 122: Medtronic SWOT Analysis, 2013 275
Table 123: Micell Technologies Company Profile 276
Table 124: Micell Technologies, Pipeline DEB Product 277
Table 125: Micell Technologies SWOT Analysis, 2013 277
Table 126: Minvasys Company Profile 278
Table 127: Minvasys, Marketed DEB Product 278
Table 128: Minvasys SWOT Analysis, 2013 279
Table 129: TriReme Medical Company Profile 279
Table 130: TriReme Medical, Pipeline DEB Product 280
Table 131: TriReme Medical SWOT Analysis, 2013 280
Table 132: Vascular Nanotransfer Technologies Company Profile 281
Table 133: Vascular Nanotransfer Technologies, Pipeline DEB Product 282
Table 134: Vascular Nanotransfer Technologies SWOT Analysis, 2013 282
Table 135: APAC Coronary and Peripheral DEB Market ($m) Forecast, 2010-2019 325
Table 136: APAC DEB Market ($m) for Treating PAD in the Lower Extremity, 2010-2019 326
Table 137: Percent of Patients with CAD or PAD Receiving Stenting with DEB Angioplasty, APAC, 2012 and 2018 (N=33) 330
Table 138: DEB Sales ($m) Forecast for Japan, 2010-2019 338
Table 139: DEB Sales ($m) Forecast for China, 2010-2019 340
Table 140: DEB Sales ($m) Forecast for India, 2010-2019 343
Table 141: Physicians Surveyed, By Country 381

1.2 List of Figures
Figure 1: Coronary Arteries of the Human Heart 30
Figure 2: Peripheral Arteries of the Lower Extremity 31
Figure 3: Pathophysiology of Coronary Artery Disease 33
Figure 4: Pathophysiology of Peripheral Artery Disease 34
Figure 5: Treatment Modalities - Coronary Artery Disease 51
Figure 6: Percent of Patients with CAD Who Receive Each Therapy Option Only, APAC, 2012 and 2019 (N=16) 52
Figure 7: Treatment Modalities - Peripheral Artery Disease 53
Figure 8: Percent of Patients with PAD Who Receive Each Therapy Option Only, APAC, 2012 (N=17) 54
Figure 9: Percent of Patients with PAD Who Receive Each Therapy Option Only, APAC, 2012 (N=17) 54
Figure 10: Drug-Eluting Balloon 63
Figure 11: Types of Stents Used to Treat CAD and PAD 69
Figure 12: Bare Metal Stent 69
Figure 13: Drug-Eluting Stent 70
Figure 14: Covered Stents 71
Figure 15: Bioabsorbable Stent - Remedy 72
Figure 16: Types of Atherectomy 74
Figure 17: Prevalence of CAD in the Population Age ?65 Years in the APAC Market (millions), 2010-2019 78
Figure 18: Prevalence of PAD in the Population Age ?65 Years in the APAC Market (millions), 2010-2019 81
Figure 19: APAC DEB Market Share for Treating Peripheral Artery Disease in the Lower Extremity, 2012 86
Figure 20: Image of the Protege DEB 104
Figure 21: Percent of CAD and PAD Patients with Acute Vessel Recoil After Standard Balloon Angioplasty, APAC, 2012 and 2018 (N=33) 159
Figure 22: Percent of CAD and PAD Patients with Thrombosis After Stenting, APAC, 2012 and 2018 (N=33) 161
Figure 23: Percent of CAD and PAD Patients with ISR, APAC, 2012 and 2018 (N=33) 162
Figure 24: Percent of CAD and PAD Patients Who Receive Stent-In-Stent Procedures, APAC, 2012 and 2018 (N=33) 163
Figure 25: Percent of CAD and PAD Patients with Stent Fracture, APAC, 2012 and 2018 (N=33) 166
Figure 26: Global DEB Pipeline Products by Stage of Development, 2013 173
Figure 27: AngioSculpt Scoring Balloon Expansion Profile 178
Figure 28: Drug-Coated Chocolate DEB 190
Figure 29: Population (? 65 years) of CAD Patients Receiving Interventional Procedures, APAC*, 2010-2019 216
Figure 30: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, APAC*, 2010-2019 217
Figure 31: Population (? 65 years) with PAD Receiving DEB Angioplasty for the Peripheral Arteries in the Lower Extremity, APAC*, 2010-2019 218
Figure 32: DEB Market for Treating CAD and PAD in the Lower Extremity, Company Share (%), 2012 235
Figure 33: DEB Market for Each Type of Disease, Company Share (%), 2012 237
Figure 34: Importance of Each Therapy Attribute in Adopting DEB for the Treatment of CAD and PAD, Global, 2012 (N=112) 298
Figure 35: APAC DEB Market ($m) for Treating Coronary Artery Disease and Peripheral Artery Disease in the Lower Extremity, 2010-2019 324
Figure 36: APAC DEB Market ($m) for Treating PAD in the Lower Extremity, 2010-2019 327
Figure 37: APAC DEB Market Share for Peripheral Artery Revascularization in the Lower Extremity , 2012 and 2019 328
Figure 38: APAC DEB Market Distribution (%) by Indication, 2012 and 2018 (N=33) 329
Figure 39: Percent of Patients with CAD Receiving Each Type of Interventional Technique Only, APAC, 2018 (N=16) 333
Figure 40: Percent of Patients with Lower Limb PAD Receiving Each Type of Interventional Technique Only, APAC, 2018 (N=17) 334
Figure 41: APAC DEB Market Revenue ($m), 2019 336
Figure 42: Japanese DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 338
Figure 43: Chinese DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 341
Figure 44: Indian DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 344

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...

Sleep Aids : Technologies and Global Markets

Sleep Aids : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

Research on the working of the human brain in relation to sleep is a fairly new area, with many new and novel theories. The discovery of new mechanisms and chemicals in the brain has provided expanding ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.